Management of Advanced Prostate Cancer in the Precision Oncology Era

Management of Advanced Prostate Cancer in the Precision Oncology Era

Prostate cancer (PC) is the second leading cause of cancer death in men in the United States. While diversified and improved treatment options for aggressive PC have improved patient outcomes, metastatic castration-resistant prostate cancer (mCRPC) remains incurable and an area of investigative ther...

Full description

Bibliographic Details
Main Authors: Claire M. Gillette, Gabriel A. Yette, Scott D. Cramer, Laura S. Graham
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
metastatic prostate cancer
advanced prostate cancer
biomarkers
genomic selection
chemotherapy
PARP inhibitors
Online Access:https://www.mdpi.com/2072-6694/15/9/2552

Internet

https://www.mdpi.com/2072-6694/15/9/2552

Similar Items